Virtual MOUD Platforms Sell Access. New Data Says They’re Selling a Detour.

The pitch from every well-funded telehealth startup treating opioid addiction sounds the same: log in from your couch, get evaluated in an afternoon, and start medication without facing a clinic’s six-week waitlist. That’s useful for someone who already has insurance, broadband, and the wherewithal to book a video visit. It’s a much less useful story for the person the industry claims to be rescuing: someone with no reliable cell signal, no primary care doctor to hand them a referral, and no idea that medication for opioid use disorder — MOUD, the buprenorphine- and methadone-based treatment that manages opioid addiction as a chronic condition rather than a moral failure — is even on the table.

The Peterson Health Technology Institute just put a number on that gap, and it isn’t flattering. PHTI’s independent assessment, covered by Fierce Healthcare, reviewed 43 studies — including 11 randomized controlled trials — plus data from 13 of the 16 virtual opioid use disorder (OUD) companies it evaluated, among them Bicycle Health, Ophelia, Pelago, Boulder Care and Workit Health. The finding: these platforms perform about as well clinically as standard in-person medication treatment, and patients stay in care an average of 13 more days over six months. A real, if modest, retention win.

It is not evidence that virtual MOUD is reaching anyone new.

PHTI found no meaningful sign that these platforms expand participation beyond people already seeking treatment, and no evidence they lower the overall cost of care — “digital wraparound” tools that layer coaching and contingency management on top of medication tend to raise net spending, because subscription costs outrun whatever savings better retention produces. That distinction matters given the scale of the problem: only one in four of the roughly 9 million U.S. adults with opioid use disorder currently receive medication treatment, and 95% of untreated people don’t believe they need it at all. A platform that makes it easier for the already-engaged quarter to stick around is not the same product as one that finds the other three-quarters — and telehealth prescribing, by definition, can’t onboard someone who never opens the app.

“Purchasers shouldn’t expect these solutions to dramatically reduce spending or expand their patient base beyond those already seeking treatment,” Caroline Pearson, executive director of the Peterson Center on Healthcare, told TechTarget — a polite way of telling every plan and employer that bought a virtual MOUD contract expecting it to reach their uninsured, untreated members that they bought a retention tool, not an outreach one.

That’s a category error this sector has profited from for years, one worth remembering the next time a technology-innovation funding round gets covered as an access story. None of this makes buprenorphine-by-video worthless — it’s a better front door for someone who already knows they want help. But PHTI’s list of who still gets left out — people without reliable devices or broadband, people facing housing instability, people who haven’t gotten past the stigma of opioid treatment in the first place — describes precisely the population these companies say justifies their valuations. None of it is a problem a login screen fixes.

If you’re evaluating a virtual MOUD provider for yourself, ask directly what happens if you need an in-person exam, detox, or a psychiatric crisis handled — telehealth prescribing still needs a plan for what video can’t cover. If you’re a case manager sizing up a virtual OUD vendor, ask the harder question: is this program adding capacity to the network, or just moving existing patients onto a nicer interface. PHTI already ran that math. The industry hasn’t had to answer it out loud until now.